Preclinical
Hide
Program-level preclinical execution view with tox signals, cohort readiness, and translational handoff metrics. Business and scientific purpose: de-risk progression to translational milestones with stronger efficacy, safety, and biomarker evidence. Preclinical is connected to linked entities, metrics, and workflow actions in this workspace. Use these panels to review evidence, identify risks, and decide the next best scientific action. The view uses deterministic demo data shaped to mirror realistic drug discovery operations.
Priority Programs
| id | name | stage | targetArea |
|---|---|---|---|
| PRG-001 | ATLAS-100 | Lead Optimisation | EGFR |
| PRG-002 | KCL-101 | Discovery | Tau |
| PRG-003 | KCL-102 | Preclinical | KRAS |
| PRG-004 | NOVA-103 | Preclinical | KRAS |
| PRG-005 | ATLAS-104 | Preclinical | Tau |
| PRG-006 | KCL-105 | Preclinical | EGFR |
| PRG-007 | ATLAS-106 | Discovery | EGFR |
| PRG-008 | KCL-107 | Discovery | EGFR |
| PRG-009 | NOVA-108 | Discovery | KRAS |
| PRG-010 | NOVA-109 | Lead Optimisation | EGFR |
| PRG-011 | KCL-110 | Preclinical | KRAS |
| PRG-012 | NOVA-111 | Discovery | EGFR |
| PRG-013 | KCL-112 | Discovery | EGFR |
| PRG-014 | ATLAS-113 | Discovery | KRAS |
| PRG-015 | ATLAS-114 | Lead Optimisation | KRAS |
| PRG-016 | KCL-115 | Preclinical | Tau |
| PRG-017 | NOVA-116 | Lead Optimisation | PD-1 |
| PRG-018 | NOVA-117 | Preclinical | IL-6 |
| PRG-019 | NOVA-118 | Discovery | KRAS |
| PRG-020 | ATLAS-119 | Lead Optimisation | PD-1 |